(Q41869433)

English

Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study

scientific article published on 30 August 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naïve Chinese patients with chronic hepatitis B: a randomized, multicenter study (English)

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

0 references

chronic hepatitis B

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Guangbi Yao

1

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Chengwei Chen

2

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Weilun Lu

3

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Hong Ren

4

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Deming Tan

5

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Yuming Wang

6

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Daozheng Xu

7

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Jessica Liu

8

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Dong Xu

9

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Cyril Llamoso

10

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

publication date

30 August 2008

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

Hepatology international

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

2

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

4

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

486-493

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

https://scigraph.springernature.com/pub.10.1007/s12072-008-9088-8

0 references

Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716907

5 June 2018

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716907

5 June 2018

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716907

5 June 2018

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716907

5 June 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716907

5 June 2018

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716907

5 June 2018

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716907

18 August 2018

Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716907

18 August 2018

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716907

18 August 2018

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716907

18 August 2018

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716907

18 August 2018

Hepatitis B e antigen and the risk of hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716907

18 August 2018

Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716907

18 August 2018

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716907

2 December 2018

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

1 reference

https://pubmed.ncbi.nlm.nih.gov/19669324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of mortality from hepatitis B and hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/19669324

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12072-008-9088-8

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41869433&oldid=1929271303"